Humacyte is trading at $0.44, up 11.06%, with no confirmed company-specific catalyst identified for October 27. - The positive V012 Phase 3 results reported October 23 predate the move and do not establish its cause. - Biotech-sector strength is a plausible backdrop: XBI was up 2.18% during the regular session, but this does not confirm what caused Humacyte’s gain. - The latest identified company news is the prior V012 results, not a new announcement today.